AR039860A1 - 1-tia-3-aza-dibenzoazulenos como inhibidores de la produccion del factor de necrosis tumoral e intermediarios para la preparacion de los mismos - Google Patents
1-tia-3-aza-dibenzoazulenos como inhibidores de la produccion del factor de necrosis tumoral e intermediarios para la preparacion de los mismosInfo
- Publication number
- AR039860A1 AR039860A1 ARP030101802A ARP030101802A AR039860A1 AR 039860 A1 AR039860 A1 AR 039860A1 AR P030101802 A ARP030101802 A AR P030101802A AR P030101802 A ARP030101802 A AR P030101802A AR 039860 A1 AR039860 A1 AR 039860A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- independently
- production
- alkylsulfinyl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000003390 tumor necrosis factor Human genes 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 3
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 2
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 abstract 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 102000000589 Interleukin-1 Human genes 0.000 abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- GOCMMZVVJOYRHM-UHFFFAOYSA-N 5-thia-3-azatetracyclo[12.4.0.02,6.08,13]octadeca-1(18),2,6,8,10,12,14,16-octaene Chemical class S1CN=C2C3=C(C4=C(C=C12)C=CC=C4)C=CC=C3 GOCMMZVVJOYRHM-UHFFFAOYSA-N 0.000 abstract 1
- 206010054094 Tumour necrosis Diseases 0.000 abstract 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000005021 aminoalkenyl group Chemical group 0.000 abstract 1
- 125000002431 aminoalkoxy group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000005014 aminoalkynyl group Chemical group 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 125000003435 aroyl group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 abstract 1
- 125000005016 hydroxyalkynyl group Chemical group 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000005188 oxoalkyl group Chemical group 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Derivados de 1-tia-3-aza-dibenzoazuleno, sus sales y solvatos farmacológicamente aceptables, procedimientos e intermediarios para la preparación de los mismos, así como también sus efectos antiinflamatorios, en especial para la inhibición de la producción del factor alfa de necrosis tumoral (TNF-alfa) e inhibición de la producción de interleuquina-1 (IL-1), como así también su acción analgésica. Reivindicación 1: Un compuesto de la fórmula (1) caracterizado porque X puede ser CH2 o un heteroátomo como ser O, S, S(=O), S(=O)2, o NRa, donde Ra es H o un grupo protector; Y y Z representan, independientemente uno del otro, uno o más sustituyentes idénticos o diferentes unidos a cualquier átomo de C disponible, y pueden ser halógeno, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, hidroxi, alcoxi C1-4, trifluorometoxi, alcanoilo C1-4, amino, aminoalquilo C1-4, N-(alquil-C1-4)amino, N,N-di(alquil-C1-4)amino, tiol, alquiltio, sulfonilo, alquilsulfonilo C1-4, sulfinilo, alquilsulfinilo C1-4, carboxi, alcoxicarbonilo C1-4, ciano,. nitro, R1 puede ser H, halógeno, un alquilo C1-7 o alquenilo C2-7 opcionalmente sustituido, alquinilo C2-7, un arilo o heteroarilo opcionalmente sustituido, y un heterociclo, hidroxi, hidroxialquenilo C2-7, hidroxialquinilo C2-7, alcoxi C1-7, tiol, tioalquenilo C2-7, tioalquinilo C2-7, alquiltio C1-7, aminoalquenilo C2-7, aminoalquinilo C2-7, aminoalcoxi C1-7, alcanoilo C1-7, aroilo, oxoalquilo C1-7, alcanoiloxi C1-7, carboxi, un (alquiloxicarbonilo o ariloxicarbonilo C1-7)opcionalmente sustituido, carbamoilo, N-(alquil C1-7)carbamoilo, N,N-di(alquil C1-7)carbamoilo, ciano, cianoalquilo C1-7, sulfonilo, alquilsulfonilo C1-7, sulfinilo, alquilsulfinilo C1-7, nitro, o un sustituyente de fórmula (2) donde R2 y R3 pueden ser simultáneamente o independientemente uno del otro, H, alquilo C1-4, arilo o conjuntamente con N tener el significado de un heterociclo o heteroarilo opcionalmente sustituido; m representa un entero que oscila entre 1 y 3; n representa un entero que oscila entre 0 y 3; Q1 y Q2 representan, independientemente uno del otro, O, S, o los grupos de fórmulas (3) donde los sustituyentes y1 e y2 pueden ser, independientemente uno del otro, H, halógeno, arilo o alquilo C1-4 opcionalmente sustituido, hidroxi, alcoxi C1-4, alcanoilo C1-4, tiol, alquiltio C1-4, sulfonilo, alquilsulfonilo C1-4, sulfinilo, alquilsulfinilo C1-4, ciano, nitro o conjuntamente forman un grupo carbonilo o imino; así como también sales y solvatos farmacológicamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HR20020451A HRP20020451A2 (en) | 2002-05-23 | 2002-05-23 | 1-tia-3-aza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039860A1 true AR039860A1 (es) | 2005-03-02 |
Family
ID=29559972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101802A AR039860A1 (es) | 2002-05-23 | 2003-05-23 | 1-tia-3-aza-dibenzoazulenos como inhibidores de la produccion del factor de necrosis tumoral e intermediarios para la preparacion de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7262302B2 (es) |
| EP (1) | EP1509532A1 (es) |
| JP (1) | JP2005529157A (es) |
| CN (1) | CN1315847C (es) |
| AR (1) | AR039860A1 (es) |
| AU (1) | AU2003232370A1 (es) |
| CA (1) | CA2486821A1 (es) |
| HR (1) | HRP20020451A2 (es) |
| IS (1) | IS7566A (es) |
| PL (1) | PL374385A1 (es) |
| RS (1) | RS100004A (es) |
| WO (1) | WO2003099827A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20020304B1 (en) * | 2002-04-10 | 2008-04-30 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof |
| HRP20030957A2 (en) * | 2003-11-21 | 2005-08-31 | Pliva-Istra�iva�ki institut d.o.o. | USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS |
| EP1844053A2 (en) * | 2005-01-13 | 2007-10-17 | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. | Anti-inflammatory macrolide conjugates |
| US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| TWI443096B (zh) | 2012-12-18 | 2014-07-01 | Ind Tech Res Inst | ３－（５－（４－（３－氟丙基）哌嗪－１－基）苯並咪唑－２－基）－１－氮雜薁－２－酮之單水合晶型及其製備方法與藥學組成物 |
| EP3595777A4 (en) * | 2017-03-14 | 2021-01-20 | Dana-Farber Cancer Institute, Inc. | LOW MOLECULAR SENSITIVITY OF BAX ACTIVATION FOR INDUCING CELL DEATH |
| CN116041360B (zh) * | 2021-10-27 | 2025-07-22 | 广州华睿光电材料有限公司 | 有机化合物及包括其的混合物、组合物和有机电子器件 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3711489A (en) * | 1971-03-31 | 1973-01-16 | Pfizer | Certain 8,9-dihydro(3,4,7,8)cycloocta(1,2-d)imidazoles |
| CA967573A (en) | 1972-12-22 | 1975-05-13 | Joseph G. Lombardino | Tetracyclic anti-inflammatory agents |
| US4198421A (en) * | 1978-11-30 | 1980-04-15 | E. I. Du Pont De Nemours And Company | Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles |
| HRP20000310A2 (en) * | 2000-05-17 | 2002-02-28 | Pliva Farmaceutska Ind Dioniko | New dibenzoazulene compounds as tumor necrosis factor inhibitors |
-
2002
- 2002-05-23 HR HR20020451A patent/HRP20020451A2/hr not_active Application Discontinuation
-
2003
- 2003-05-20 US US10/515,700 patent/US7262302B2/en not_active Expired - Fee Related
- 2003-05-20 AU AU2003232370A patent/AU2003232370A1/en not_active Abandoned
- 2003-05-20 JP JP2004507484A patent/JP2005529157A/ja active Pending
- 2003-05-20 WO PCT/HR2003/000023 patent/WO2003099827A1/en not_active Ceased
- 2003-05-20 CA CA002486821A patent/CA2486821A1/en not_active Abandoned
- 2003-05-20 CN CNB038161060A patent/CN1315847C/zh not_active Expired - Fee Related
- 2003-05-20 EP EP03755235A patent/EP1509532A1/en not_active Withdrawn
- 2003-05-20 RS YU100004A patent/RS100004A/sr unknown
- 2003-05-20 PL PL03374385A patent/PL374385A1/xx not_active Application Discontinuation
- 2003-05-23 AR ARP030101802A patent/AR039860A1/es unknown
-
2004
- 2004-11-29 IS IS7566A patent/IS7566A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20020451A2 (en) | 2003-12-31 |
| JP2005529157A (ja) | 2005-09-29 |
| WO2003099827A1 (en) | 2003-12-04 |
| PL374385A1 (en) | 2005-10-17 |
| US7262302B2 (en) | 2007-08-28 |
| IS7566A (is) | 2004-11-29 |
| RS100004A (sr) | 2006-10-27 |
| CN1315847C (zh) | 2007-05-16 |
| AU2003232370A1 (en) | 2003-12-12 |
| EP1509532A1 (en) | 2005-03-02 |
| US20060111340A1 (en) | 2006-05-25 |
| CN1665822A (zh) | 2005-09-07 |
| CA2486821A1 (en) | 2003-12-04 |
| HK1081949A1 (en) | 2006-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044909A1 (es) | Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia | |
| AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
| PE20030269A1 (es) | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas | |
| PE20080888A1 (es) | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) | |
| DK1052254T3 (da) | Nitrogen-holdig heterocykliske derivater og medicin deraf | |
| AR060957A1 (es) | Derivados de tiazolo-pirimidina / piridina-urea | |
| AR061642A1 (es) | Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas | |
| DOP2002000349A (es) | Nuevos compuestos antiinflamatorios de bencimidazol | |
| ECSP045476A (es) | Tiazolidinonas, su preparación y su uso como medicamentos | |
| AR088218A1 (es) | Compuestos heterociclicos utiles como inhibidores de pi3k | |
| PE20070589A1 (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| CO5590919A2 (es) | Derivados de pirimidina como moduladores de receptor de factor-1 de crecimiento similara la insulina (igf-1) | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR039860A1 (es) | 1-tia-3-aza-dibenzoazulenos como inhibidores de la produccion del factor de necrosis tumoral e intermediarios para la preparacion de los mismos | |
| AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
| MX2022015886A (es) | Derivados de amidopirimidona. | |
| PE20061013A1 (es) | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias | |
| CL2024004060A1 (es) | Compuestos heterocíclicos inhibidores de axl; composición farmacéutica; uso para tratar cáncer. | |
| BR0311767A (pt) | Compostos inibidores de sulfonamida substituìda da produção de beta amilóide, suas composições e usos | |
| AR118784A1 (es) | Compuesto de amida que tiene acción inductora de la degradación de la proteína bet y su uso como medicamento | |
| AR131006A1 (es) | Compuestos novedosos | |
| AR040040A1 (es) | 1,3-diaza-dibenzoazulenos para la inhibicion de la produccion del factor de necrosis tumoral e intermediarios para su preparacion | |
| AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| ECSP066542A (es) | Derivados de disulfuro, sulfuro, sulfóxido, y sulfota de azúcares cíclicos y sus usos | |
| AR066604A1 (es) | Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |